These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 22382202

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Thyroid dysfunction in patients treated with sunitinib or sorafenib.
    Clemons J, Gao D, Naam M, Breaker K, Garfield D, Flaig TW.
    Clin Genitourin Cancer; 2012 Dec; 10(4):225-31. PubMed ID: 23017335
    [Abstract] [Full Text] [Related]

  • 5. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Daimon M, Kato T, Kaino W, Takase K, Karasawa S, Wada K, Kameda W, Susa S, Oizumi T, Tomita Y, Kato T.
    Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Kidney cancer: Does hypothyroidism predict clinical outcome?
    Rini B.
    Nat Rev Urol; 2011 Jan; 8(1):10-1. PubMed ID: 21116300
    [No Abstract] [Full Text] [Related]

  • 8. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC.
    Cancer; 2011 Feb 01; 117(3):534-44. PubMed ID: 20845482
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
    Shu M, Zai X, Zhang B, Wang R, Lin Z.
    PLoS One; 2016 Feb 01; 11(1):e0147048. PubMed ID: 26784451
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
    Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H.
    J Clin Oncol; 2008 Nov 10; 26(32):5204-12. PubMed ID: 18838713
    [Abstract] [Full Text] [Related]

  • 17. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
    Wong MK, Jarkowski A.
    Pharmacotherapy; 2009 Apr 10; 29(4):473-8. PubMed ID: 19323623
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.
    Aktuelle Urol; 2009 Jan 10; 40(1):31-6. PubMed ID: 19177319
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.